NPS+ HIV (EU5) - New Market Study Published

Monotherapies trailing fixed-dose combinations for HIV. Where does your brand rank?

Which HIV treatment gets the best satisfaction scores from Infectious Disease specialists? In Europe it isn't even close. Find which brand is miles ahead of the rest, how your brand compares, and how single-pill monotherapies are faring against popular combination treatments.

FirstView's NPS+ HIV report compares brand loyalty for 8 major HIV treatments-information you can use to improve your brand's health, and boost your market share.

Based on your net promoter score (NPS), the report shows you how likely doctors are to recommend your brand-and your competitors. Plus you'll learn which brand messages drive recommendations, and get candid thoughts about your brand from prescribing Infectious Disease specialists.

Full Report Details at
- http://www.fastmr.com/prod/1152011_nps+_hiv_eu5.aspx?afid=301

Intuitive, easy-to-use KPIs highlight areas for improvement and make your next steps crystal clear.

Not your market? Click here to see the US Edition.

Get Answers to Key Questions about HIV Treatments

* Celsentri (Maraviroc; ViiV Healthcare): What is the only brand message that resonates with more than 50% of Celsentri Promoters?
* Evotaz (Atazanavir/Cobicistat; Bristol-Myers Squibb/Gilead): Is lack of availability stopping Detractors from recommending Evotaz?
* Intelence (Entravirine; Janssen Pharma): Which EU5 country's doctors have the most positive feedback about Intelence?
* Isentress (Raltegravir; Merck & Co.): Isentress and Stribild have roughly equal numbers of Promoters. Which has the higher NPS?
* Stribild (Elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat; Gilead): Which other brand is recommended by nearly 75% of Stribild Promoters?
* Triumeq (Abacavir/dolutegravir/lamivudine; ViiV Healthcare): Which brands stand to gain more market share by winning over Detractors, Triumeq or Stribild?
* Truvada (Emtricitabine/tenofovir disoproxil fumarate; Gilead): What promotional message is least effective with Truvada Promoters, Detractors, and Passives?
* Viread (Tenofovir disoproxil fumarate; Gilead): In the US, Viread has a positive NPS and equal numbers of Promoters and Detractors. How does it fare in Europe?

Top Takeaways

* One brand dominates: Half of the surveyed brands have a positive NPS, but the leading brand scores more than one-and-a-half times higher than its closest competitor.
* Market leader doesn't get top NPS: Although one mainstay brand has an overwhelming lead in market share, a newer brand earns a slightly higher NPS.
* Satisfaction lower than in US: In Europe, nearly 15% fewer doctors are satisfied with available HIV treatments than in the US.
* Fixed-dose combination therapies lead: Combination therapies outscore monotherapies overall, earning 3 of the top 4 NPS scores.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- NPS+ HIV (US)
- NPS+ Renal Cell Carcinoma (EU5)
- PharmaPoint: Human Immunodeficiency Virus (HIV) - Global Drug Forecast and Market Analysis to 2023
- EpiCast Report: Human Immunodeficiency Virus (HIV) - Epidemiology Forecast to 2023
- NPS+ Renal Cell Carcinoma (US)